Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions. Its current portfolio includes approved therapies for transthyretin-mediated amyloidosis, and the company also advances programs in areas such as hypertension and other genetically defined diseases. Alnylam Pharmaceuticals works across the United States, Europe, and other international markets, supporting patients through specialized treatments and healthcare partnerships. Headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals plays a significant role in the growing RNAi medicine segment, where it is recognized for translating gene-silencing science into commercial therapies for serious conditions.